Fluzone Intradermal Vaccine Approved for Influenza Immunization

FLUZONE INTRADERMAL (influenza virus vaccine) by Sanofi Pasteur
FLUZONE INTRADERMAL (influenza virus vaccine) by Sanofi Pasteur
Sanofi Pasteur announced that the FDA has approved Fluzone Intradermal (influenza virus vaccine) for the active immunization of adults 18–64 years old against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. This approval was based on data from a Phase 3 clinical trial in 4,276 adults 18–64 years old that showed systemic reactogenicity of Fluzone Intradermal vaccine to be comparable to that of intramuscular administration of Fluzone vaccine.

Fluzone Intradermal uses a novel microinjection system featuring an ultra-fine needle that is that is 0.06 inches (1.5mm) in length and contains 9mcg of hemagglutinin per strain of influenza in a 0.1mL dose. Fluzone, given intramuscularly, is administered utilizing a needle 1–1.5 inches (25–38mm) in length and contains 15mcg of hemagglutinin per strain of influenza in a 0.5mL dose.

Fluzone Intradermal will be available for the upcoming 2011–2012 influenza season.

For more information call (800) VACCINE or visit www.sanofipasteur.us.